SEARCH

SEARCH BY CITATION

References

  • ABRAMOVITZ, M., ADAM, M., BOIE, Y., CARRIERE, D.D., GODBOUT, C., LAMONTAGNE, S., ROCHETTE, C., SAWYER, N., TREMBLAY, N.M., BELLEY, M., GALLANT, M., DUFRESNE, C., GAREAU, Y., RUEL, R., JUTEAU, H., LABELLE, M., OUIMET, N. & METTERS, K. (2000). The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim. Biophys. Acta., 1483, 285293.
  • ABRAMOVITZ, M., ADAM, M., BOIE, Y., GRYGORCZYK, R., RUSHMORE, T.H., NGUYEN, T., FUNK, C.D., BASTIEN, L., SAWYER, N., ROCHETTE, C., SLIPETZ, D.M. & METTERS, K.M. (1995). Human prostanoid receptors: cloning and characterization. Adv. Prost. Thromb. Leuk. Res., 23, 499504.
  • ADAM, M., BOIE, Y., RUSHMORE, T.H., MULLER, G., BASTIEN, L., MCKEE, K.T., METTERS, K.M. & ABRAMOVITZ, M. (1994). Cloning and expression of three isoforms of the human EP3 prostanoid receptor. FEBS Letts., 338, 170174.
  • ARUNLAKSHANA, O. & SCHILD, H.O. (1959). Some quantitative uses of drug antagonists. Br. J. Pharmacol., 14, 4858.
  • BILLOT, X., CHATEAUNEUF, A., CHAURET, N., DENIS, D., GREIG, G., MATHIEU, M.C., METTERS, K.M., SLIPETZ, D.M. & YOUNG, R.N. (2003). Discovery of a potent and selective agonist of the prostaglandin EP4 receptor. Bioorg. Med. Chem. Letts., 13, 11291132.
  • BIRDSALL, N.J., COHEN, F., LAZARENO, S. & MATSUI, H. (1995). Allosteric regulation of G-protein-linked receptors. Biochem. Soc. Trans., 23, 108111.
  • BOIE, Y., SAWYER, N., SLIPETZ, D.M., METTERS, K.M. & ABRAMOVITZ, M. (1995). Molecular cloning and characterization of the human prostanoid DP receptor. J. Biol. Chem., 270, 1891018916.
  • BRITTAIN, R.T., BOUTAL, L., CARTER, M.C., COLEMAN, R.A., COLLINGTON, E.W., GEISOW, H.P., HALLETT, P., HORNBY, E.J., HUMPHREY, P.P., JACK, D., KENNEDY, I., LUMLEY, P., MCCABE, P.J., SKIDMORE, I.F., THOMAS, M. & WALLIS, C.J. (1985). AH23848: a thromboxane receptor-blocking drug that can clarify the pathophysiologic role of thromboxane A2. Circulation, 72, 12081218.
  • CHENG, Y.C. & PRUSOFF, W.H. (1973). Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 percent inhibition (IC50) of an enzyme reaction. Biochem. Pharmacol., 22, 30993108.
  • COLEMAN, R.A., MALLETT, A. & SHELDRICK, R.L.G. (1995). EP4-receptors and cyclic AMP in pig venous smooth muscle: evidence with agonists and the EP4 antagonist, AH 22921. In: Advances in Prostaglandin, Thromboxane and Leukotriene Research. eds. Samuelsson, B., Paoletti, R. & Ramwell, P. Vol. 23. pp. 241246. New York: Raven.
  • COLEMAN, R.A., SMITH, W.L. & NARUMIYA, S. (1994). International Union of Pharmacology VIII. Classification of prostanoid receptors: properties, distribution and structure of the receptors and their subtypes. Pharmacol. Rev., 46, 205229.
  • CRIDER, J.Y., GRIFFIN, B.W. & SHARIF, N.A. (2000). Endogenous EP4 prostaglandin receptors coupled positively to adenylyl cyclase in Chinese hamster ovary cells: pharmacological characterization. Prost. Leuk. Essent. Fatty Acids, 62, 2126.
  • DAVIS, R.J., MURDOCH, C.E., ALI, M., PURBRICK, S., RAVID, R., BAXTER, G.S., TILFORD, N., SHELDRICK, R.L., CLARK, K.L. & COLEMAN, R.A. (2004). EP4 prostanoid receptor-mediated vasodilatation of human middle cerebral arteries. Br J. Pharmacol., 141, 580585.
  • GIBLIN, G.M.P., WILSON, R.J., FOORD, S.M., SWARBRICK, M., WALKER, A., BAMFORD, M., ROOMANS, S., MASON, A., MILLER, N., JONES, H., SHANAHAN, S., RASMUSSEN, S., SMITH, L., SPALDING, D., RANSHAW, L., FENWICK, R., ANCLIFF, R., SAEZ, V., FRYE, S., STRATTON, S., LEWELL, X., CARTWRIGHT, K.A., RHODES, S., ROBERTS, N. & GREEN, R. (2002). A Novel, selective, non-prostanoid EP4 receptor antagonist. Poster at 224th ACS Natl Meet (August 18–22, 2002, Boston) Abst MEDI-306.
  • HATTORI, K., TANAKA, A., FUJI, N., TAKASUGI, H., TENDA, Y., TOMITA, M., NAKAZATO, K., KATO, Y., KONO, Y., MURAI, H. & SAKANE, K. (2005). Discovery of diphenyloxazole and -Z-ornithine derivatives as highly potent and selective human prostaglandin EP4 receptor antagonists. J. Med. Chem., 48, 31033106.
  • HIRAI, H., TANAKA, K., YOSHIE, O., OGAWA, K., KENMOTSU, K., TAKAMORI, Y., ICHIMASA, M., SUGAMURA, K., NAKAMURA, M., TAKANO, S. & NAGATA, K. (2001). Prostaglandin D2 selectively induces chemotaxis in T-helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J. Exp. Med., 193, 225261.
  • HIRATA, T., USHIKUBI, F., KAKIZUKA, A., OKUMA, M. & NARUMIYA, S. (1994). Two thromboxane A2 receptor isoforms in human platelets: opposite coupling to adenylate cyclase with different sensitivity to Arg60 to Leu mutation. J. Clin. Invest., 97, 949956.
  • HUGHES, G.C., POST, M.J., SIMONS, M. & ANNEX, B.H. (2003). Translational physiology: porcine models of human coronary artery disease: implications for preclinical trials of therapeutic angiogenesis. J. App. Physiol., 94, 16891701.
  • JONES, R.L. & CHAN, K.M. (2005). Investigation of the agonist activity of prostacyclin analogues on prostanoid EP4 receptors using GW 627368 and taprostene: evidence for species differences. Prost. Leuk. Essent. Fatty Acids., 72, 289299.
  • KOTANI, M., TANAKA, I., OGAWA, Y., USUI, T., MORI, K., ICHIKAWA, A., NARUMIYA, S., YOSHIMI, T. & NAKAO, K. (1995). Molecular cloning and expression of multiple isoforms of human prostaglandin E receptor EP3 Subtype generated by alternative messenger RNA splicing – multiple second messenger systems and tissue-specific distributions. Mol. Pharmacol., 48, 869879.
  • LAZARENO, S. & BIRDSALL, N.J. (1995). Detection, quantitation, and verification of allosteric interactions of agents with labeled and unlabeled ligands at G protein-coupled receptors: interactions of strychnine and acetylcholine at muscarinic receptors. Mol. Pharmacol., 48, 362378.
  • LEFF, P. (1996). The two-state model of agonist action: challenges to pharmacological receptor theory. Proc. Western Pharmacol. Soc., 39, 6768.
  • LEW, M.J. & ANGUS, J.A. (1985). Analysis of competitive agonist-antagonist interactions by nonlinear regression. Trends Pharmacol. Sci., 16, 328337.
  • LI, M., KE, H.Z., QI, H., HEALY, D.R., LI, Y., CRAWFORD, D.T., PARALKAR, V.M., OWEN, T.A., CAMERON, K.O., LEFKER, B.A., BROWN, T.A. & THOMPSON, D.D. (2003). A novel, non-prostanoid EP2 receptor-selective prostaglandin E2 agonist stimulates local bone formation and enhances fracture healing. J. Bone Min. Res., 18, 20332042.
  • LUNDSTROM, K. (2002). Semliki forest virus-based expression for versatile use in receptor research. J. Recept. Sig. Trans., 22, 229240.
  • LYDFORD, S.J., MCKECHNIE, K.C.W. & LEFF, P. (1996). Interaction of BW A868C, a prostanoid DP-receptor antagonist, with two receptor subtypes in the rabbit isolated saphenous vein. Prostaglandins, 52, 125139.
  • MACHWATE, M., HARADA, S., LEU, C.T., SEEDOR, G., LABELLE, M., GALLANT, M., HUTCHINS, S., LACHANCE, N., SAWYER, N., SLIPETZ, D., METTERS, K.M., RODAN, S.B., YOUNG, R. & RODAN, G.A. (2001). Prostaglandin receptor EP4 mediates the bone anabolic effects of PGE2. Mol. Pharmacol., 60, 3641.
  • MARSHALL, F.H., PATEL, K., LUNDSTROM, K., CAMACHO, J., FOORD, S.M. & LEE, M.G. (1997). Characterization of [3H]-prostaglandin E2 binding to prostaglandin EP4 receptors expressed with semliki forest virus. Br. J. Pharmacol., 121, 16731678.
  • MODY, S.M., HO, M.K.C., JOSHI, S.A. & WONG, Y.H. (2000). Incorporation of Gz-specific sequence at the carboxyl terminus increases the promiscuity of G16 toward Gi-coupled receptors. Mol. Pharmacol., 57, 1323.
  • MUTOH, M., WATANABE, K., KITAMURA, T., SHOJI, Y., TAKAHASHI, M., KAWAMORI, T., TANI, K., KOBAYASHI, M., MARUYAMA, T., KOBAYASHI, K., OHUCHIDA, S., SUGIMOTO, Y., NARUMIYA, S., SUGIMURA, T. & WAKABAYASHI, K. (2002). Involvement of prostaglandin E receptor subtype EP4 in colon carcinogenesis. Cancer Res., 62, 2832.
  • NARUMIYA, S., SUGIMOTO, Y. & USHIKUBI, F. (1999). Prostanoid receptors: structures, properties and functions. Phys. Rev., 79, 11931226.
  • OGAWA, M., HARADA, H., KADODE, M., MATSUOKA, H., MATSHUSHITA, Y., SAGAWA, K., YOSHIDA, H., MARUYAMA, T., TANI, K., OHUCHIDA, S. & KONDO, K. (2000). Development of ONO-8815, a potent and selective agonist of the prostaglandin E receptor EP2 subtype. 11th International Conference on Advances in Prostaglandin and Leukotriene Research: Basic Science and New Clinical Applications. Florence, Italy, June 4th–8th, 2000.
  • OXFORD, A.W., DAVIS, R.J., COLEMAN, R.A., CLARK, K.L., CLARK, D.E., HARRIS, N.V., FENTON, G., HYND, G., STUTTLE, K.A.J., SUTTON, J.M., ASHTON, M.R., BOYD, E.A. & BRUNTON, S.A. (2005). EP2 receptor agonists. WO 2005/080367 A1.
  • PALOMER, A., CABRE, F., PASCUAL, J., CAMPOS, J., TRUJILLO, M.A., ENTRENA, A., GALLO, M.A., GARCIA, L., MAULEON, D. & ESPINOSA, A. (2002). Identification of novel cyclooxygenase-2 selective inhibitors using pharmacophore models. J. Med. Chem., 45, 14021411.
  • SAKATA, K., MARUYAMA, T., SEKI, A., YOSHIDA, H., SHINAGAWA, Y., KONDO, K. & OHUCHIDA, S. (2000). The roles of PGE2 receptor EP4 subtype on cytokine regulation and its related diseases. 11th International Conference on Advances in Prostaglandin and Leukotriene Research: Basic Science and New Clinical Applications. Florence, Italy, June 4th–8th, 2000.
  • TANI, K., NAGANAWA, A., ISHIDA, A., KOBAYASHI, K., SAGAWA, K., OGAWA, M. & OHUCHIDA, S. (2000). Synthesis and structure-activity relationships of potent and selective EP2 receptor agonists. 11th International Conference on Advances in Prostaglandin and Leukotriene Research: Basic Science and New Clinical Applications. Florence, Italy, June 4th–8th, 2000.
  • TSUBOI, K., SUGIMOTO, Y. & ICHIKAWA, A. (2002). Prostanoid receptor subtypes. Prost. Other Lip. Med., 68–69, 535556.
  • WILSON, R.J. & GILES, H. (2005). Piglet saphenous vein contains multiple relaxatory prostanoid receptors: evidence for EP4, EP2, DP & IP receptor subtypes. Br. J. Pharmacol., 144, 405415.
  • WILSON, R.J., GIBLIN, G.M.P., FOORD, S.M., SWARBRICK, M., WALKER, A., BAMFORD, M., ROOMANS, S., MASON, A., MILLER, N., JONES, H., SHANAHAN, S., RASMUSSEN, S., SMITH, L., SPALDING, D., RANSHAW, L., FENWICK, R., ANCLIFF, R., SAEZ, V., FRYE, S., STRATTON, S., LEWELL, X., CARTWRIGHT, K.-A., K-A RHODES, S., ROBERTS, N. & GREEN, R. (2003). GW627368X: a Novel, potent and selective EP4 prostanoid receptor antagonist. Br. J. Pharmacol., 138, 84P.
  • WISE, H. (1999). Characterisation of chimeric prostacyclin/prostaglandin D2 receptors. Eur. J. Pharmacol., 386, 8996.
  • WRIGHT, D.H., METTERS, K.M., ABRAMOVITZ, M. & FORDHUTCHINSON, A.W. (1998). Characterization of the recombinant human prostanoid DP receptor and identification of L-644,698, a novel selective DP agonist. Br. J. Pharmacol., 123, 13171324.
  • YAMAMOTO, H., MARUYAMA, T., SAKATA, K., KOKETSU, M., KOBAYASHI, M., YOSHIDA, H., SEKI, A., TANI, K., MARUYAMA, T., KONDO, K. & OHUCHIDA, S. (1999). Novel four selective agonists for prostaglandin E receptor subtypes. Prost. Lip. Med., 59, 150.
  • YANG, J.H., XIA, M.H., GOETZL, E.J. & AN, S.Z. (1994). Cloning and expression of the EP3-subtype of human receptors for prostaglandin E2. Biochem. Biophys. Res. Comms., 198, 9991006.